PRODUCT

Introduction to Boryung
caring for people’s health

Main Products

A guide to Boryung’ main
products.

Products

A guide to all
Boryung’s products.

close

R&D

The Boryung Company,
envisioning a world with a
healthy mankind.

R&D Vision·Strategy

Boryung’ goal is to develop
into a global company.

Pipeline

The research team at Boryung
aims to lead the future of the
pharmaceutical industry.

close

GLOBAL
BUSINESS

An introduction of
Boryung’ global business.

Introduction

The best global company.

CMO

Introducing BRCMO business

Network

50 markets and 150 partners worldwide.

close

PR

An introduction of Boryung ’ value -
Envisioning a healthy mankind.

Advertising

An introduction of video
and printed advertisements of Boryung.

close

Directions

An introduction of Boryung
Pharmaceutical’ value - Envisioning
a healthy mankind.

Directions

An introduction of video
and printed advertisements of Boryung.

close

Financial Information

Summary of Consolidated Statements of Financial Position

(Unit : KRW 1,000,000 / As of December 31, 2025)

Summary of Consolidated Statements of Financial Position
Financial items 2025 2024 2023
Current assets 662,938 631,574 377,659
Non-current assets 724,942 532,513 537,852
Total assets 1,387,880 1,164,087 915,512
Current liabilities 254,965 239,339 201,083
Non-current liabilities 287,412 140,244 165,176
Total liabilities 542,378 379,584 366,259
Issued capital 43,394 43,394 34,345
Capital surplus & Other comprehensive income/loss accumulated amount 283,301 274,469 107,468
Retained earnings 518,808 466,641 406,936
Total equity 845,503 784,503 549,253

Summary of Consolidated Statements of Comprehensive Income

(Unit : KRW 1,000,000 / As of December 31, 2025)

Summary of Consolidated Statements of Comprehensive Income
Financial items 2025 2024 2023
Revenue 1,017,427 1,017,107 859,626
Cost of sales 645,145 653,750 506,196
Gross profit 372,282 363,357 353,430
Selling, general and administrative expenses 242,126 241,415 237,877
R&D expenses 65,089 51,469 47,286
Operating profit 65,067 70,472 68,267
Finance income 38,853 47,329 7,098
Finance costs 30,850 42,149 11,834
Other gains 3,345 1,529 1,385
Other losses 4,796 10,931 4,564
Share of loss of associates -1,769 -3,291 -4,048
Profit before tax 69,849 62,959 56,306
Income tax expense 5,547 -6,676 16,092
Net profit 64,303 69,636 40,213
Total comprehensive income 69,805 67,297 37,293

Major financial ratio

(Unit : KRW 1,000,000 / As of December 31, 2025)

Major financial ratio
Financial items 2025 2024 2023
Revenue growth rate 0.03% 18.32% 13.04%
Profit growth rate -7.66% 73.17% -4.11%
ROA 4.63% 5.98% 4.45%
ROE 7.61% 8.88% 7.55%
Debt ratio 64.15% 48.39% 66.68%
Reserve ratio 1195.58% 1075.36% 1184.85%
Interest coverage ratio (times) 5.62 7.83 7.15

Analysis on profitability

(Unit : KRW 1,000,000 / As of December 31, 2025)

Analysis on profitability
Financial items 2025 2024 2023
Gross profit margin 36.59% 35.72% 41.11%
R&D investment ratio 6.40% 5.06% 6.04%
Selling, general and administrative expenses ratio 23.80% 23.74% 27.67%
Operating profit margin 6.40% 6.93% 7.94%
Net profit margin 6.32% 6.85% 4.68%
TOP